CWLXFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends March 31

C21 Investments Inc.

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 12, 2026

Share price

Not available yet

Price, market cap and P/E appear here once daily prices are connected.

Debt

Borrowings on the balance sheet, Mar 31, 2026

C21 Investments reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in C21 Investments's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in C21 Investments's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CWLXF.

Revenue growth15.3% · median 6.4%

Gross margin41.7% · median 34.8%

Operating margin7.0% · median -26.4%

Company	Revenue	Growth
CGC	C$293.63M	+6.8%
JUSH	$271.75M	+6.0%
CWLXF	$32.61M	+15.3%
LEEEF	–	–
GLAS	–	–
IMCC	–	–

Company

Exchange: OTC
Industry: Medicinal Chemicals & Botanical Products
Fiscal year ends: March 31
Auditor: Davidson & Company LLP
SEC CIK: 831609

Advertisement
300 × 250